Ipca Laboratories Q1FY22 consolidated Net Total Income at Rs1586.81cr; Stock ends 2% higher

Consolidated Net Profit down 31% in Q1FY22 at Rs306.67cr. EBIDTA margin at 27.36%.

Aug 05, 2021 04:08 IST India Infoline News Service

Ipca Laboratories Limited on Thursday reported standalone Net Total Income at Rs1492.21cr in Q1FY22 as against Rs1496.93cr in Q1FY21. Consolidated Net Total Income at Rs1586.81cr in Q1FY22 as against Rs1546.49cr in Q1FY21. Exports Income at Rs766.27cr in Q1FY22 as against Rs773.89cr in Q1FY21.

Standalone EBIDTA margin (before forex (gain)/loss) at 27.10% in Q1FY22 as against 39.65% in Q1FY21. Consolidated EBIDTA margin at 27.36% in Q1FY22 as against 38.44% in Q1FY21. Standalone Net Profit down 37% at Rs284.72cr. Consolidated Net Profit down 31% at Rs306.67cr.

Total Formulations revenue stood at Rs1054.77cr in Q1FY22, a rise of 11% compared to Rs953.05cr in Q1FY21. Total APIs revenue was at Rs414.42cr in Q1FY22, a decline of 19% compared to Rs513.29cr in Q1FY21.

Ipca is a fully integrated pharmaceutical company with a strong thrust on exports. Ipca is vertically integrated and produces Finished Dosage Forms (PDFs) and Active Pharmaceutical Ingredients (APIs).

Ipca Laboratories Ltd ended at Rs2,130.10 up by Rs42.55 or 2.04% from its previous closing of Rs2,087.55 on the BSE. The company stock touched day's high of Rs2242.50 per piece near 52-week high of Rs2245.55 per piece on Thursday.

Related Story

Open Free Demat Account (Rs699)